APA (7th ed.) Citation

Lin, R. S., Mukhopadhyay, P., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., . . . Iacona, R. (2023). Comment on "Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials" by the Cross-Pharma Non-Proportional Hazards Working Group. Statistics in Biopharmaceutical Research, 15(2), 312. https://doi.org/10.1080/19466315.2022.2103180

Chicago Style (17th ed.) Citation

Lin, Ray S., et al. "Comment on "Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials" by the Cross-Pharma Non-Proportional Hazards Working Group." Statistics in Biopharmaceutical Research 15, no. 2 (2023): 312. https://doi.org/10.1080/19466315.2022.2103180.

MLA (9th ed.) Citation

Lin, Ray S., et al. "Comment on "Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials" by the Cross-Pharma Non-Proportional Hazards Working Group." Statistics in Biopharmaceutical Research, vol. 15, no. 2, 2023, p. 312, https://doi.org/10.1080/19466315.2022.2103180.